Ion Channels in Drug Discovery—a Granular Report Addressing Pharmaceutical Companies Target Market

Prevalence of Parkinsons disease, autoimmune dysfunction and cardiac arrhythmias has brought a paradigm shift in their treatment through ion channel modulators. The rising footprint of drug discovery has furthered the penetration of ion channels. Drug discovery, with the support of ion channel targeted mechanism of action, accounts for around 12% to 15% of the research studies. Moreover, in 2022, there were 19% of marketed drugs, further validating ion channels as the third largest group of target proteins in drug discovery.

Ion channel-based drug development will be pronounced following the completion of human genome sequencing in April 2022. Pharmaceutical companies could unlock growth potentials with an infusion of funds into RD activities and outsourcing.

Assessment of ligand-gated ion channels and voltage-gated channels.

Insights on preclinical development, target identification screening, target validation functional informatics and lead identification candidate optimization.

Deliberate upon potassium-, calcium- and sodium channels.

Competitive landscape and inputs on the ion channel drug discovery outsourcing services

Get your copy or request for a free sample of the report Ion Channels in Drug Discovery, 2023 Report, compiled and published by Grand View Research.

Ion Channels in Drug Discovery Report Scope